https://www.selleckchem.com/pr....oducts/semaglutide.h
092 vs. no adjuvant therapy) and chemotherapy combined with radiotherapy (adjusted HR 0.18) were associated with improved disease-specific survival in the NSMP subgroup (n=218). In contrast, adjuvant therapies showed no effect on disease-specific survival in the full MMR-D cohort (n=287) or in MLH1 methylated tumors (n=154). Whole pelvic radiotherapy (adjusted HR 25 vs. no adjuvant therapy/vaginal brachytherapy) and chemotherapy combined with whole pelvic radiotherapy (adjusted HR 32) were associated with poor disease-specific survi
Like
Comment
Share
